REPL Replimune Group Inc

Price (delayed)

$7.65

Market cap

$469.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.16

Enterprise value

$446.12M

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary ...

Highlights
Replimune Group's quick ratio has decreased by 48% YoY and by 3.1% from the previous quarter
The net income has contracted by 34% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of REPL
Market
Shares outstanding
61.39M
Market cap
$469.62M
Enterprise value
$446.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$202.92M
EBITDA
-$200.44M
Free cash flow
-$176.27M
Per share
EPS
-$3.16
Free cash flow per share
-$2.64
Book value per share
$7.14
Revenue per share
$0
TBVPS
$8
Balance sheet
Total assets
$532.93M
Total liabilities
$111.39M
Debt
$75.81M
Equity
$421.54M
Working capital
$440.51M
Liquidity
Debt to equity
0.18
Current ratio
12.4
Quick ratio
12.22
Net debt/EBITDA
0.12
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-35.8%
Return on equity
-42.9%
Return on invested capital
-40.1%
Return on capital employed
-41.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REPL stock price

How has the Replimune Group stock price performed over time
Intraday
-1.03%
1 week
6.92%
1 month
1.73%
1 year
-69.18%
YTD
-9.25%
QTD
-9.25%

Financial performance

How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$229.01M
Net income
-$209.96M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 47% year-on-year and by 7% since the previous quarter
The net income has contracted by 34% YoY and by 6% from the previous quarter

Growth

What is Replimune Group's growth rate over time

Valuation

What is Replimune Group stock price valuation
P/E
N/A
P/B
1.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 10% YoY and by 2.6% QoQ
REPL's price to book (P/B) is 60% lower than its 5-year quarterly average of 2.7 and 44% lower than its last 4 quarters average of 1.9
The company's equity fell by 29% YoY and by 9% QoQ

Efficiency

How efficient is Replimune Group business performance
REPL's ROE is down by 23% YoY and by 15% QoQ
Replimune Group's return on assets has decreased by 16% YoY and by 12% QoQ
Replimune Group's return on invested capital has decreased by 8% QoQ and by 3.4% YoY

Dividends

What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REPL.

Financial health

How did Replimune Group financials performed over time
Replimune Group's quick ratio has decreased by 48% YoY and by 3.1% from the previous quarter
REPL's current ratio is down by 47% YoY and by 2.8% QoQ
Replimune Group's debt is 82% less than its equity
The debt to equity has surged by 80% year-on-year and by 38% since the previous quarter
The company's equity fell by 29% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.